Company & Sponsor Intelligence

Sunnybrook Health Sciences Centre

Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.

Request enterprise analysis →

Indexed trials7

Recruiting2

Completed3

Countries1

Therapeutic footprint

alzheimersbipolar_disorderdepression

Indexed studies

NCT07477431Levetiracetam for Persons at Risk for Alzheimer's Disease
alzheimers · CanadaPHASE2

NCT03670615Using Exercise and Electrical Brain Stimulation to Improve Memory in Dementia
alzheimers · CanadaNA

NCT01928043Adjunctive Curcumin for Symptomatic Adolescents With Bipolar Disorder: Brain and Body Considerations
bipolar_disorder · CanadaPHASE2

NCT05374213Virtual Mindfulness Intervention RCT
depression · CanadaNA

NCT02593643Effect of Ketamine vs. Active Placebo on Suicidal Ideation in Depressed Inpatients With Major Depressive Disorder or Bipolar Depression.
depression · CanadaEARLY_PHASE1

NCT07279740Combined Brain Stimulation and Methylphenidate Treatment for Apathy in Dementia
alzheimers · CanadaPHASE2

NCT06178731Virtual Reality Reward Training and Transcranial Magnetic Stimulation for Depression
depression · CanadaNA

Intelligence layer updated: 2026-10-14 06:11:28.884102+00:00

Enterprise intelligence

Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.

Request comparative intelligence →